X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PRX123 is a wholly-owned potential first-in-class dual Aβ/tau vaccine. It is being evaluated in IND-enabling studies for the treatment of Alzheimer's Disease.
Lead Product(s): PRX123
Therapeutic Area: Neurology Product Name: PRX123
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2024
Details:
Under the collaboration, Bristol will obtain the exclusive worldwide commercial rights for PRX005, a best-in-class anti-tau antibody that specifically binds with high affinity the R1, R2, and R3 repeats within the MTBR of tau and targets both 3R and 4R tau isoforms.
Lead Product(s): PRX005
Therapeutic Area: Neurology Product Name: PRX005
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: $2,200.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration July 11, 2023
Details:
The collaboration aims to accelerate patient identification and recruitment for Prothena’s ASCENT-2 clinical trial evaluating the safety and tolerability of PRX012, a potential best-in-class anti-amyloid beta antibody under development for the treatment of Alzheimer’s disease.
Lead Product(s): PRX012
Therapeutic Area: Neurology Product Name: PRX012
Highest Development Status: Phase IProduct Type: Large molecule
Recipient: Walgreens
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2023
Details:
PRX005 is an anti-tau antibody that specically binds with high anity the R1, R2, and R3 repeats within the MTBR of tau and targets both 3R and 4R tau isoforms. Neurobrillary tangles composed of misfolded tau proteins, with amyloid beta plaques in alzheimer’s disease.
Lead Product(s): PRX005
Therapeutic Area: Neurology Product Name: PRX005
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 31, 2023
Details:
Birtamimab, formerly known as NEOD001, is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.
Lead Product(s): Birtamimab,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Jefferies
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering December 13, 2022
Details:
PRX004 is an investigational humanised monoclonal antibody designed to deplete amyloid associated with disease pathology that underlies hereditary and wild type ATTR amyloidosis, without affecting the native, normal tetrameric form of the protein.
Lead Product(s): NNC6019
Therapeutic Area: Genetic Disease Product Name: NNC6019
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Novo Nordisk
Deal Size: $1,200.0 million Upfront Cash: $100.0 million
Deal Type: Acquisition November 21, 2022
Details:
Birtamimab is an investigational monoclonal antibody designed to specifically and selectively target and clear the amyloid that accumulates and causes organ dysfunction and failure in patients with AL amyloidosis.
Lead Product(s): Birtamimab,Cyclophosphamide,Bortezomib
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Preclinical data have also demonstrated clearance of both pyroglutamate modified and unmodified Aβ plaque in brain tissue at concentrations of PRX012 estimated to be clinically achievable in the central nervous system with subcutaneous delivery.
Lead Product(s): PRX012
Therapeutic Area: Neurology Product Name: PRX012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 26, 2022
Details:
Preclinical data have shown that PRX012 binds to beta amyloid plaques and oligomers with high avidity, enabling effective levels of Aβ plaque occupancy at relatively lower dose ranges, which are optimal for subcutaneous delivery.
Lead Product(s): PRX012
Therapeutic Area: Neurology Product Name: PRX012
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 28, 2022
Details:
Results showed that participants with PD who were treated with prasinezumab for two years showed slower decline of Movement Disorder Society-Unified Parkinson’s Disease Rating Scale Part 3 scores relative to participants treated with prasinezumab for one year.
Lead Product(s): Prasinezumab
Therapeutic Area: Neurology Product Name: RO7046015
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 16, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
